Author

Alastair D. Reith

GlaxoSmithKline (United Kingdom)ORCID 0000-0001-5092-0604Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:CRISPR screen· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Approach:machine learning (classical)· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Alessio StranoiD· 1 shared Alice RockliffeiD· 1 shared Andrew R. Bassett· 1 shared Anna TasegianiD· 1 shared Ashley Campbell· 1 shared Benedetta Carbone· 1 shared Benjamin FalconiD· 1 shared Bernardino Francesco GhettiiD· 1 shared

Activity by Year

2020-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Alessio StranoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NeurosciencebioRxivPreprintJun 10, 2025

A CRISPR-CAS9 high throughput machine-learning platform for modulation of genes involved in Parkinson's disease-associated PINK1-mitophagy in iPSC-derived dopaminergic neurons

Marc P. M. Soutar, Benedetta Carbone, Petya Kindalova…·Hélène Plun‐Favreau

The paper develops a CRISPR-CAS9 platform with machine learning to study PINK1-mitophagy in Parkinson's disease using iPSC-derived neurons, identifying key genes and validating their roles.

DOI 10.1101/2025.06.10.658840

humanCRISPR screen

𝕏 PostBluesky

NeuroscienceBiochemical JournalPeer-reviewedSep 13, 2021

Impact of Type II LRRK2 inhibitors on signalling and mitophagy

Anna Tasegian, François Singh, Ian G. Ganley…·Dario R. Alessi

This study compares Type I and Type II LRRK2 inhibitors, showing Type II compounds are more potent against wild-type LRRK2 and fail to dephosphorylate specific biomarker sites, suggesting conformational selectivity.

70 citationstop 3%

humanproteomics

𝕏 PostBluesky

NeurosciencebioRxivPreprintAug 11, 2020

Whole genome CRISPR screens identify a LRRK2-regulated pathway for extracellular tau uptake by human neurons

Lewis Evans, Alessio Strano, Eleanor J. Tuck…·Frederick J. Livesey

The paper identifies LRRK2-regulated pathways for extracellular tau uptake in human neurons using CRISPR screens, showing LRRK2's role in monomeric tau endocytosis.

19 citations

humanCRISPR screen

𝕏 PostBluesky